Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers

Video

Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.

At the 2022 International Gastric Cancer Conference, Sam Klempner, MD, of Massachusetts General Hospital, spoke to CancerNetwork® about the role of circulating tumor DNA (ctDNA) in patients with nonmetastatic gastroesophageal cancer and which patient populations are most likely to have have recurrence of their disease.

Transcript:

The main clinical question driving the interest in incorporating ctDNA into [the management of] nonmetastatic gastroesophageal cancers is that despite our best therapies—which are intensive and often toxic, including triplet chemotherapy and surgery in gastric cancer—we still have high recurrence rates. Identifying groups of patients who are either more or less likely to recur, and ultimately, by using some of these tests to incorporate into management, we may be able to define groups that we could intensify or potentially even de-intensify therapy for and achieve the same outcomes with a potentially less toxic regimen. The currently poor outcomes, the lack of current clinical predictors, and the potential toxicity of our treatments are the things that are driving better biomarkers.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Related Content